Literature DB >> 11777558

Treatment of experimental autoimmune myasthenia gravis with recombinant human tumor necrosis factor receptor Fc protein.

Premkumar Christadoss1, Elzbieta Goluszko.   

Abstract

Lymphotoxin-alpha (TNF-beta) and TNF receptor p55 gene knockout mice are resistant to the development of antibody and complement mediated experimental autoimmune myasthenia gravis (EAMG), suggesting a possible role of TNF in mediating EAMG. Therefore, we tested the hypothesis that blocking the functional interaction of TNF with their receptors by soluble recombinant human TNFR:Fc would suppress the ongoing clinical EAMG. Recombinant human TNFR:Fc administered daily for 2 weeks to C57BL6 mice with ongoing clinical EAMG significantly improved clinical EAMG when compared with placebo-treated mice. A clinical trial of selected myasthenia gravis patients with recombinant human TNFR:Fc could be attempted.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11777558     DOI： 10.1016/s0165-5728(01)00473-8

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN： 0165-5728            Impact factor:   3.478


  12 in total

Review 1.  Treatment of myasthenia gravis: focus on pyridostigmine.

Authors:  Lorenzo Maggi; Renato Mantegazza
Journal:  Clin Drug Investig       Date:  2011-10-01       Impact factor: 2.859

2.  Interleukin-10 plays a key role in the modulation of neutrophils recruitment and lung inflammation during infection by Streptococcus pneumoniae.

Authors:  Hernán F Peñaloza; Pamela A Nieto; Natalia Muñoz-Durango; Francisco J Salazar-Echegarai; Javiera Torres; María J Parga; Manuel Alvarez-Lobos; Claudia A Riedel; Alexis M Kalergis; Susan M Bueno
Journal:  Immunology       Date:  2015-09       Impact factor: 7.397

Review 3.  Myasthenia gravis: an update for the clinician.

Authors:  J P Sieb
Journal:  Clin Exp Immunol       Date:  2014-03       Impact factor: 4.330

Review 4.  Myasthenia gravis: past, present, and future.

Authors:  Bianca M Conti-Fine; Monica Milani; Henry J Kaminski
Journal:  J Clin Invest       Date:  2006-11       Impact factor: 14.808

5.  Widely varying TNF-alpha levels in patients with myasthenia gravis.

Authors:  Jin Soo Lee; In Soo Joo; Jung Im Seok
Journal:  Neurol Sci       Date:  2009-02-13       Impact factor: 3.307

6.  T cells as pioneers: antigen-specific T cells condition inflamed sites for high-rate antigen-non-specific effector cell recruitment.

Authors:  Saeed Ghani; Markus Feuerer; Cornelia Doebis; Uta Lauer; Christoph Loddenkemper; Jochen Huehn; Alf Hamann; Uta Syrbe
Journal:  Immunology       Date:  2009-03-26       Impact factor: 7.397

Review 7.  Molecular and genetic aspects of guanylyl cyclase natriuretic peptide receptor-A in regulation of blood pressure and renal function.

Authors:  Kailash N Pandey
Journal:  Physiol Genomics       Date:  2018-08-31       Impact factor: 3.107

Review 8.  Advances in autoimmune myasthenia gravis management.

Authors:  Shuhui Wang; Iva Breskovska; Shreya Gandhy; Anna Rostedt Punga; Jeffery T Guptill; Henry J Kaminski
Journal:  Expert Rev Neurother       Date:  2018-07-04       Impact factor: 4.618

9.  Myasthenia gravis: a review.

Authors:  Annapurni Jayam Trouth; Alok Dabi; Noha Solieman; Mohankumar Kurukumbi; Janaki Kalyanam
Journal:  Autoimmune Dis       Date:  2012-10-31

10.  Fatigue and muscle atrophy in a mouse model of myasthenia gravis is paralleled by loss of sarcolemmal nNOS.

Authors:  Sarina Meinen; Shuo Lin; Markus A Rüegg; Anna Rostedt Punga
Journal:  PLoS One       Date:  2012-08-28       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.